Earnings Summary

Axsome Therapeutics, Inc.’s revenue jumped +Inf% since last year same period to $94.58Mn in the Q1 2023. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 288.06% jump in its revenue since last 3-months.

Axsome Therapeutics, Inc.’s net profit jumped 71.69% since last year same period to $-11.22Mn in the Q1 2023. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 81.68% jump in its net profits since last 3-months.

Axsome Therapeutics, Inc.’s net profit margin jumped NaN% since last year same period to -11.86% in the Q1 2023. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 95.28% jump in its net profit margins since last 3-months.

Axsome Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.09 - a -0.93% fall from last quarter’s estimates.

Axsome Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -1.09.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Axsome Therapeutics, Inc.’s return on assets (ROA) stands at -0.37.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Axsome Therapeutics, Inc.’s return on equity (ROE) stands at -2.51.